[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100138167":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":30,"centralContacts":34,"locations":35,"responsibleParty":74,"collaborators":34,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":34,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":34,"enrollmentInfo":85,"targetDuration":34,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":95,"whyStopped":96,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Repros Therapeutics Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"50 mg Proellex®","ACTIVE_COMPARATOR","2, 25 mg capsules",[13],"Drug: Proellex",{"label":15,"type":10,"description":16,"interventionNames":17},"25 mg Proellex®","1, 25 mg capsule",[13],[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Proellex","2, 25 mg capsules once per day",[9],[25],"CDB-4124",{"type":20,"name":21,"description":27,"armGroupLabels":28,"otherNames":29},"1, 25 mg capsule once per day",[15],[25],[31],{"name":32,"affiliation":5,"role":33},"Andre vanAS, PhD, Md","STUDY_DIRECTOR",null,[36,49,58,68],{"facility":37,"status":34,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":34},"Visions Clinical Research","Boynton Beach","Florida","33472","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-80.06643,26.52535,{"lat":47,"lon":46},{"facility":50,"status":34,"city":51,"state":39,"zip":52,"country":41,"countryCode":42,"cosmosGeoPoint":53,"geoPoint":57,"contacts":34},"Insignia Clinical Research (Tampa Bay Women's Center)","Tampa","33067",{"type":44,"coordinates":54},[55,56],-82.45843,27.94752,{"lat":56,"lon":55},{"facility":59,"status":34,"city":60,"state":61,"zip":62,"country":41,"countryCode":42,"cosmosGeoPoint":63,"geoPoint":67,"contacts":34},"Advances in Health Inc","Houston","Texas","77030",{"type":44,"coordinates":64},[65,66],-95.36327,29.76328,{"lat":66,"lon":65},{"facility":69,"status":34,"city":60,"state":61,"zip":70,"country":41,"countryCode":42,"cosmosGeoPoint":71,"geoPoint":73,"contacts":34},"The Women's Hospital of Texas, Clinical Research Center","77054",{"type":44,"coordinates":72},[65,66],{"lat":66,"lon":65},{"type":75,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100138167","phase-3-safety-of-25-and-50-mg-proellex-in-the-treatment-of-women-with-symptomatic-uterine-fibroids-100138167",true,"NCT01069120","Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids","A Phase III Multicenter Extension Study Evaluating the Safety of 25 and 50 mg Proellex® in the Treatment of Women Who Have Completed ZPU-301, ZPU-302, ZPU-303, or ZPU-304","Inclusion Criteria:\n\n* At least 1 uterine fibroid must be identifiable and measurable by Transvaginal Ultrasound (TVU)\n* Subject has a menstrual cycle lasting from 20 to 40 days.\n* Subject must have satisfactorily completed all study visits from the previous study in which she participated: ZPU-301, ZPU-302, ZPU-303, or ZPU-304\n\nExclusion Criteria:\n\n* Subjects who have not participated in 1 of the previous Repros studies: ZPU-301, ZPU-302, ZPU-303, or ZPU-304.\n* Subjects who met treatment stopping rules as per the DILI Guidance requirements while participating in ZPU-301, ZPU-302, ZPU-303, or ZPU-304","FEMALE","18 Years",{"count":86,"type":87},27,"ACTUAL","INTERVENTIONAL",[90],"PHASE3","Safety and efficacy study of 25 and 50 mg doses of Proellex",[93],"Uterine Fibroids",[93],"TERMINATED","Repros stopped study due to safety and FDA placed study on hold","2014-08-05",{"date":99,"type":100},"2014-08-21","ESTIMATED",{"date":102,"type":34},"2009-04",{"date":104,"type":87},"2009-08",{"name":5,"class":6},4]